Elgan Pharma, specialising in neonatology, and Italy-based biopharma, Chiesi Farmaceutici, have announced the dosing of the first participating infants in FIT-PIV, a phase 3 clinical study of ELGN-2112, a prospective treatment for intestinal malabsorption in preterm infants. The FIT-PIV study is expected to roll 420 infants, born 26-32 weeks and weighing at least 500g, at […]
The post Study into treatment for rare condition in premature infants launches globally appeared first on Pharmafile.
